Filter Results
:
(3)
Show Results For
-
All HBS Web
(3)
- Research (3)
- Faculty Publications (3)
Show Results For
-
All HBS Web
(3)
- Research (3)
- Faculty Publications (3)
Page 1 of
3
Results
- February 2015 (Revised November 2015)
- Supplement
Building an Integrated Biopharma Company: Crucell (B)
By: Richard G. Hamermesh, Marianne Van Der Steen and Susan Harmeling
The Crucell (B) case updates events at Crucell since 2009. In September, 2009, Johnson & Johnson acquired 18% of Crucell for $400 million. This investment was part of a business development deal. Subsequently, in 2012, Johnson & Johnson acquired Crucell for $2.8...
View Details
Keywords:
Biotechnology;
Biopharmacy Company;
Licensing Agreements In Biopharmacy;
Licensing;
Human Cell-line Technology;
Vaccine;
Healthcare Innovation;
Global Health;
Entrepreneurship;
Health Care and Treatment;
Acquisition;
Innovation and Invention;
Biotechnology Industry;
Pharmaceutical Industry
Hamermesh, Richard G., Marianne Van Der Steen, and Susan Harmeling. "Building an Integrated Biopharma Company: Crucell (B)." Harvard Business School Supplement 815-086, February 2015. (Revised November 2015.)
- February 2015 (Revised November 2015)
- Case
Building an Integrated Biopharma Company: Crucell (A)
By: Richard G. Hamermesh, Marianne Van Der Steen and Susan S. Harmeling
By 2009, Crucell had become the largest biopharma company in the Netherlands and a symbol of national pride. The case traces the evolution of the company from a University spin-off into a fully-integrated company. Crucell's success, particularly in the vaccine space,...
View Details
Keywords:
Biotechnology;
Biopharmacy Company;
Licensing;
Licensing Agreements In Biopharmacy;
Human Cell-line Technology;
Vaccine;
Healthcare Innovation;
Global Health;
Partners and Partnerships;
Entrepreneurship;
Growth and Development Strategy;
Biotechnology Industry;
Pharmaceutical Industry;
Netherlands
Hamermesh, Richard G., Marianne Van Der Steen, and Susan S. Harmeling. "Building an Integrated Biopharma Company: Crucell (A)." Harvard Business School Case 815-085, February 2015. (Revised November 2015.)
- January 2020
- Case
Celata Bioinnovations
By: John R. Wells and Benjamin Weinstock
In December 2019, Jon Hu (HBS ‘19) and Dr. Samantha Dale Strasser, co-founders of Celata Bioinnovations, were raising $1 million to launch their company. They had founded Celata less than six months earlier with the aim of redefining the drug discovery process....
View Details
Keywords:
Drug Development;
Drug Discovery;
Drug Trials;
Pharmaceutical Companies;
Pharmaceutical Company;
Pharmaceuticals;
Therapeutics;
Biologics;
Biotech;
Biotechnology;
Biopharmacy Company;
Biochemistry;
Technology Commercialization;
Technology Companies;
Drug Testing;
Startup;
Start-up;
Startups;
Start-ups;
Startup Financing;
Strategic Decision Making;
Strategic Decisions;
Strategic Evolution;
FDA;
Food And Drug Administration;
Clinical Trials;
Disease Management;
Market Attractiveness;
Market Entry;
Market Opportunities;
Health Disorders;
Technological Innovation;
Information Technology;
Commercialization;
Business Startups;
Finance;
Decision Making;
Strategy;
Market Entry and Exit;
Opportunities;
Pharmaceutical Industry;
Biotechnology Industry
Wells, John R., and Benjamin Weinstock. "Celata Bioinnovations." Harvard Business School Case 720-427, January 2020.